1. Scrip
  2. >>Business
  3. >>Strategy

Amgen To Rapidly Move Olpasiran Into Phase III For Lp(a) Reduction

 
• By Jessica Merrill

The siRNA drug demonstrated a significant reduction in lipoprotein(a) from baseline of up to or greater than 90% for the majority of doses in a Phase II trial; Novartis has a potential first-to-market advantage.

chess piece advancing
Amgen is advancing olpasiran into Phase III • Source: Shutterstock

Amgen, Inc. plans to move quickly into a Phase III development program with its cardiovascular drug candidate olpasiran, a small interfering RNA drug targeting lipoprotein(a), following a successful Phase II study. There are no approved drugs to lower Lp(a) levels, but Amgen is behind rival Novartis AG in the effort to bring the first to market; Novartis has the Lp(a)-targeting drug pelacarsen in Phase III development.

Amgen said it hopes to advance olpasiran quickly. "In parallel to the Phase II program, we've been planning a Phase...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Capricor Gets Complete Response For DMD Cell Therapy

 
• By Joseph Haas

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

Bayer Bags First Global Okay For Hot Flashes Therapy

 
• By Kevin Grogan

Lynkuet will compete with Astellas's Veozah/Veoza

Merck & Co. Remains In The BD Game After Verona Takeout

 
• By Jessica Merrill

CEO Rob Davis said the company is in pursuit of more deals as it looks to close the revenue gap looming from the loss of Keytruda in 2028.

Asia Deal Watch: JCR And Alexion Build Upon Existing Gene Therapy Alliances

 
• By Joseph Haas, Lisa Takagi, Sushmita Panda, and Anju Ghangurde

Plus deals involving TandemAI/Perpetual Medicines, Biocytogen/BeOne, Chugai/Gero, CStone/Istituto Gentili, Alembic/Utility, Brii/Joincare, HanchorBio/Henlius, Rakuten/Cyntec and more.

More from Business

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 
• By Anju Ghangurde

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 
• By Alaric DeArment

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

Merck & Co. Remains In The BD Game After Verona Takeout

 
• By Jessica Merrill

CEO Rob Davis said the company is in pursuit of more deals as it looks to close the revenue gap looming from the loss of Keytruda in 2028.